Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Daniel N. Swisher, Jr. net worth and biography

Daniel Swisher, Jr. Biography and Net Worth

Director of Cerus

Mr. Swisher has served as a member of our Board since June 2011 and has served as Chair of the Board since October 2013. He was appointed President and Chief Operating Officer of Jazz Pharmaceuticals as of January 2018. From December 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. In addition to serving on Cerus’ Board, he currently serves as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions.

What is Daniel N. Swisher, Jr.'s net worth?: The estimated net worth of Daniel N. Swisher, Jr. is at least $194,611.68 as of November 10th, 2022. Mr. Swisher, Jr. owns 113,808 shares of Cerus stock worth more than $194,612 as of April 28th. This net worth approximation does not reflect any other assets that Mr. Swisher, Jr. may own. Learn More about Daniel N. Swisher, Jr.'s net worth.
How do I contact Daniel N. Swisher, Jr.?: The corporate mailing address for Mr. Swisher, Jr. and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Daniel N. Swisher, Jr.'s contact information.
Has Daniel N. Swisher, Jr. been buying or selling shares of Cerus?: Daniel N. Swisher, Jr. has not been actively trading shares of Cerus over the course of the past ninety days. Most recently, Daniel N. Swisher, Jr. sold 12,500 shares of the business's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $3.91, for a transaction totalling $48,875.00. Following the completion of the sale, the director now directly owns 113,808 shares of the company's stock, valued at $444,989.28. Learn More on Daniel N. Swisher, Jr.'s trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, Cerus insiders bought shares 3 times. They purchased a total of 22,500 shares worth more than $38,875.00. In the last year, insiders at the biotechnology company sold shares 6 times. They sold a total of 177,516 shares worth more than $372,911.99. The most recent insider tranaction occured on March, 14th when CFO Kevin Dennis Green sold 21,497 shares worth more than $42,349.09. Insiders at Cerus own 7.1% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 3/14/2024.

Daniel N. Swisher, Jr. Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/10/2022	Sell	12,500	$3.91	$48,875.00	113,808
8/4/2021	Sell	12,877	$6.25	$80,481.25	106,231
5/18/2021	Sell	5,000	$5.75	$28,750.00	64,868
11/17/2020	Sell	10,000	$6.25	$62,500.00	69,868

Daniel N. Swisher, Jr. Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $1.71

$1.67

$1.72

50 Day Range

MA: $1.95

$1.64

$2.42

2 Week Range

Now: $1.71

$1.21

$3.08

Volume

387,036 shs

Average Volume

900,610 shs

Market Capitalization

$309.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad